50 results about "Peak plasma" patented technology

A method of administering beta-hydroxy-beta-methylbutyric acid (HMB) is described, and specifically administering HMB-acid to a person such that the administration of free acid HMB results in an increase in effectiveness of HMB over administration of other forms of HMB, including a calcium salt HMB composition is described. Administration of HMB-acid results in an increase in the peak level of HMB in plasma compared with administration of a similar dose of a calcium salt HMB composition. Administration of HMB-acid results in a faster time to reach peak plasma levels of HMB relative to administration of a similar dosage of a calcium salt HMB composition.

Novel controlled release pharmaceutical compositions for oral use containing midodrine and/or its active metabolite desglymidodrine. The novel compositions are designed to release midodrine and/or desglymidodrine after oral intake in a manner which enables absorption to take place in the gastrointestinal tract so that a relatively fast peak plasma concentration of the active metabolite desglymidodrine is obtained followed by a prolonged and relatively constant plasma concentration of desglymidodrine.

The novel compositions may be designed for administration once or twice daily, i.e. a therapeutically effective concentration of desglymidodrine is maintained for a period of at least 10-16 hours followed by a wash out period of about 8-12 hours in order to avoid the well-known midodrine related side effect with respect to supine hypertension. The therapeutically effective concentration of desglymidodrine is regarded as a plasma concentration of desglymidodrine of at least about 3 ng/ml. A composition is designed to release midodrine and/or desglymidodrine in at least the following consecutive steps: i) an initial relatively fast release of midodrine and/or desglymidodrine (in order to obtain a relatively fast onset of action), ii) a steady release or a slower release than in step 1 of midodrine and/or desglymidodrine (in order to maintain a plasma concentration of desglymidodrine which is prolonged and relatively constant), iii) a second rise in release of midodrine and/or desglymidodrine (in order to take advantage of absorption from the colon, i.e. such a second rise release is designed to take place when the composition (or the disintegrated parts of the composition) reaches the colon; normally this is regarded to take about 8 hours after oral intake, and iv) a decline in release rate corresponding to that essentially all midodrine and/or desglymidodrine have been released from the composition.

Also disclosed is a method for treating orthostatic hypotension and/or urinary incontinence, the method comprising administration to a patient in need thereof of an effective amount of midodrine and/or desglymidodrine in a composition according to the invention.

Novel phannaceutcal kit comprising a controlled release pharmaceutical compositions for oral use containing midodrine and/or its active metabolite desglymidodrine and a relatively fast onset composition. The controlled release compositions are designed to release midodrine and/or desglymidodrine after oral intake in a manner which enables absorption to take place in the gastrointestinal tract so that a relatively fast peak plasma concentration of the active metabolite desglymidodrine is obtained followed by a prolonged and relatively constant plasma concentration of desglymidodrine. The controlled release compositions may be designed for administration once or twice daily, i.e. a therapeutically effective concentration of desglymidodrine is maintained for a period of at least 10-16 hours followed by a wash out period of about 8-12 hours in order to avoid the well-known midodrine related side effect with respect to supine hypertension. The therapeutically effective concentration of desglymidodrine is regarded as a plasma concentration of desglymidodrine of at least about 3 ng/ml. A composition is designed to release midodrine and/or desglymidodrine in at least the following consecutive steps; i) an initial relatively fast release of midodrine and/or desglymidodrine (in order to obtain a relatively fast onset of action), ii) a steady release or a slower release than in step 1 of midodrine and/or desglymidodrine (in order to maintain a plasma concentration of desglymidodrine which is prolonged and relatively constant), iii) a second rise in release of midodrine and/or desglymidodrine (in order to take advantage of absorption from the colon, i.e. such a second rise release is designed to take place when the composition (or the disintegrated parts of the composition) reaches the colon; normally this is regarded to take about 8 hours after oral intake, and iv) a decline in release rate corresponding to that essentially all midodrine and/or desgtymidodrine have been released from the composition. One of the advantages of the invention is that the controlled release composition provides a base line plasma concentration, which during most of the day is therapeutically effective. When a higher concentration is needed, only a minor supply of active drug substance is necessary to obtain a very fast relief from symptoms. If the constant base line plasma concentration was absent, it would be necessary to use a relative higher fast onset dose to reach the high therapeutically effective level. The kit according to the present invention is a superior tool for obtaining an optimal treatment with a minimum of active drug substance. Also disclosed is a method for treating orthostaic hypotension and/or urinary incontinence, the method comprising administration to a patient in need thereof of an effective amount of midodrine and/or desglymidodrine in a kit according to the invention.

Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (C_max) and slightly delaying the peak such as to avoid activating the dopaminergic and adrenergic receptors, while achieving sufficient active binding to the serotonin receptors to provide relief from migraine symptoms within a timeframe that permits rapid resolution of migraine symptoms. Inhaler devices suitable for the methods are disclosed. Kits for practicing the methods of invention are disclosed.

Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37° C. of from about 12.5% to about 42.5% (by wt) opioid released after 1 hour, from about 25% to about 65% (by wt) opioid released after 2 hours, from about 45% to about 85% (by wt) opioid released after 4 hours, and greater than about 60% (by wt) opioid released after 8 hours, the in-vitro release rate being substantially independent of pH and chosen such that the peak plasma level of said opioid analgesic obtained in-vivo occurs from about 2 to about 8 hours after administration of the dosage form.

The invention relates to an oral solid drug dosage form containing montelukast sodium as a single active drug. The dosage form is prepared from a slow-release kernel and a quick-release outer layer, wherein the slow-release kernel can be prepared from blank-pellets coated by slow-release garments after loading a drug, also can be prepared from a main drug and other proper slow-release macromolecule after extrusion and spheronization, and then the quick-release outer layer is prepared on the slow-release kernel in a manner of loading the drug; the pellets can be filled into the capsules or tabletted. Compared with a common preparation, the novel pulsed release capsules disclosed by the invention achieve the peak plasma concentration at the moment that asthma easily breaks out before dawn; the target of enough time to treat can be met; the medication availability and security of an asthma patient are improved.

To solve the problem of an obvious side effect existing in the traditional Tripterygium Hypoglaucum Hutch root tablet, the invention provides a bi-layer extended release tablet which can reduce medicine peak plasma concentration. A Tripterygium Hypoglaucum Hutch root extract is any one extract of the whole Tripterygium Hypoglaucum Hutch root, Tripterygium Hypoglaucum Hutch root bark, or Tripterygium Hypoglaucum Hutch root core with the bark removed. The Tripterygium Hypoglaucum Hutch extract bi-layer extended release tablet has the characteristics of little untoward effect, and is convenient and safe to use. At the same time, a medicine-time curve is stable, the plasma concentration has small fluctuations, and the half life is prolonged. The Tripterygium Hypoglaucum Hutch root extract extended release bi-layer tablet using the root core with the bark removed has good therapeutic effects on asthma, lupus erythematosus, nephritis, and rheumatoid arthritis.

Novel modified release pharmaceutical compositions wherein the composition comprises at least one antibiotic(s) preferably amoxicillin or its pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof either alone or in combination with other antibiotic(s) as active ingredient, with at least one release modifying agent(s) for controlling the release of the beta lactam antibiotic optionally with one or more other pharmaceutically acceptable excipient(s) is provided, wherein the dosage form provides a release of not more than about 60% of the antibiotic in about 30 minutes and not less than about 70% of the antibiotic after 8 hours when subjected to in vitro dissolution study or when tested in vivo. Further, the compositions of the present invention which when tested in a group of healthy humans provide a mean peak plasma concentration (C_max) after at least about 0.5 hour of administration of the dosage form. The present invention also provides process of preparing such dosage form and methods of using such dosage form.

The novel positively charged pro-drugs of oxicams and related compounds in the general formula (1) 'Structure 1' were designed and synthesized. The positively charged amino groups of these pro-drugs not only largely increases the solubility of the drugs, but also bonds to the negative charge on the phosphate head group of membranes and pushes the pro-drug into the cytosol. The results suggest that the pro-drugs diffuses through human skin approximately 100 times faster than do oxicams and related compounds. It takes 1-2 hours for oxicams and related compounds to reach the peak plasma level when they are taken orally, but these prodrugs only took about approximately 50 minutes to reach the peak plasma level when they are taken transdermally. In plasma, more than 90% of these pro-drugs can change back to the parent drugs in a few minutes. The prodrugs can be used medicinally in treating any oxicams-treatable conditions in humans or animals. Second, the prodrugs can be administered not only orally, but also transdermally for any kind of medical treatments and avoid most of the side effects of oxicams. Controlled transdermal administration systems of the prodrugs enable oxicams and related compounds to reach constantly optimal therapeutic blood levels to increase effectiveness and reduce the side effects of oxicams and related compounds. Another great benefit of the transdermal administration of these pro-drugs is that administering medication, especially to children, will be much easier.

The invention discloses a dual transmission peak plasma optical fiber sensor based on an asymmetric opening ring structure. The sensor comprises a metal film and a periodic opening ring slit array structure formed on the metal film, wherein a single periodic structure is composed of left and right opening ring slits, and two opening ring slits having the same inner and outer radius but different central angles are horizontally located on the left and right sides in the middle of the unit. The sensor structure provided by the invention has a dual transmission peak characteristic of a high quality factor and high transmittance in a near-infrared frequency band, and the sensitivity of the sensor can be further improved and the sensor can be operated in two different frequency bands by using the characteristic. At the same time, the purpose of adjusting the spectral position of the dual transmission peak can be achieved by modifying the relevant structural parameters, thereby realizing a plasma optical fiber sensor with a wide working frequency band, wide application range, high sensitivity and easy processing.

The invention discloses a multi-transmission peak plasma filter based on a MIM waveguide coupling cavity structure, which is characterized in that the multi-transmission peak plasma filter mainly comprises a metal film and a plurality of slit structural units formed on the metal film; the slit structural units are composed of a plurality of lateral rectangular slits and a plurality of longitudinalrectangular slits which pass through upper and lower surfaces of the metal film; two lateral rectangular slit structural units at the same level of the lower end of the metal film are an incident tube and an exit tube of a waveguide; and three lateral rectangular slits and four longitudinal rectangular slit structural units above the waveguide in the metal film form a unified overall resonant cavity. The filter structure of the invention has tunable and high transmittance characteristics in the infrared band; the size of a transmission spectrum and a frequency selection position can be effectively adjusted by changing relevant parameters of the structure, so that the output characteristics of the filter are changed. The research results show that the highest transmittance can reach 93%, the transmittance of each transmission peak is 75% or more, the half-height width can reach below 10nm, and the quality factor can reach 122.81. The optimal filtering effect can be obtained by changingthe relevant parameters of the structure. The multi-transmission peak filter device has the advantages of wide application range, high utilization rate, easy integration, flexible application, etc.,and thus has good application prospect in all-optical networks.

The invention relates to an improved release dosage form of febuxostat and a preparation method thereof. Specifically, the febuxostat preparation of the present invention consists of febuxostat granules or pellets with different release properties. The preparation can effectively reduce the peak value of drug concentration in blood plasma, prolong drug action time, reduce side effects and improve patient compliance.

The invention discloses a piribedil sustained release preparation and a preparation method thereof. The piribedil sustained release preparation comprises 40-50 weight parts of piribedil, 90-120 weight parts of filling agent, 25-40 weight parts of sustained release material, 0.1-0.2 weight parts of binding agent, and 0.25-0.5 weight parts of lubricant. The preparation method comprises the following steps: firstly respectively crushing piribedil, the filling agent and the sustained release material and fully mixing to obtain mixed powder; then adding the binding agent and uniformly mixing to obtain a soft material; preparing the soft material into wet particles, and drying to obtain dry particles; and adding the lubricant to prepare into piribedil sustained release tablets. According to the invention, the piribedil sustained release preparation disclosed herein can effectively reduce the peak plasma concentration and prolong the action time of the drug, so as to improve the pathological cognition and sensory nerve dysfunction of patients and improve the pain symptoms caused by arterial disease of patients, and the curative effect is significant.

Pharmaceutical modified release dosage form comprising at least one cyclooxygenase enzyme inhibitor or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof as active agent, with a pharmaceutically acceptable carrier for controlling the release of the cyclooxygenase enzyme inhibitor is provided. The dosage form preferably provides a release of not more than about 60% of the cyclooxygenase enzyme inhibitor in 1 hour and not less than about 75% of the cyclooxygenase enzyme inhibitor after 12 hours when tested in accordance with the dissolution method (I) described herein employing Distilled water with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (II) described herein employing pH 7.0 Phosphate buffer with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (III) described herein employing 0.001 N Hydrochloric acid with 1.0% Sodium lauryl sulphate as dissolution medium. Further, the pharmaceutical composition of the present invention when tested in a group of healthy humans preferably achieves a mean peak plasma concentration (C_max) after at least about 1 hour of administration of the dosage form. The present invention also provides process of preparing such dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form.

The novel positively charged pro-drugs of arylanthranilic acids in the general formula (1) 'Structure 1' were designed and synthesized. The compounds of the general formula (1) 'Structure 1' indicated above can be prepared from mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds, by reaction with suitable alcohols, thiols, or amines and coupling reagents, such as N, N'-Dicyclohexylcarbodiimide, N, N'-Diisopropylcarbodiimide, O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, Benzotriazol-1-yl-oxy-tris (dimethylamino)phosphonium hexafluorophosphate, et al. The positively charged amino groups of these pro-drugs not only largely increases the solubility of the drugs, but also bonds to the negative charge on the phosphate head group of membranes and pushes the pro-drug into the cytosol. The results suggest that the pro-drugs diffuses through human skin ~200 times faster than does mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds. It takes 2-4 hours for mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds to reach the peak plasma level when they are taken orally, but these prodrugs only took about ~50 minutes to reach the peak plasma level when they are taken transdermally. In plasma, more than 90% of these pro-drugs can change back to the parent drugs in a few minutes. The prodrugs can be used medicinally in treating any NSAIAs-treatable conditions in humans or animals. The prodrugs can be administered not only orally, but also transdermally for any kind of medical treatments and thus avoid most of the side effects of NSAIAs, most notably GI disturbances such as dyspepsia, gastroduodenal bleeding, gastric ulcerations, and gastritis.

The present application discloses pharmaceutical compositions for modified release of huperzine. The pharmaceutical compositions and methods described herein, allow for dosing of huperzine at higher therapeutic thresholds, while avoiding rapid serum peak plasma levels, thereby avoiding the adverse nausea and vomiting associated with the immediate release pharmaceutical compositions. Methods of treating neurological disorders and/or seizure disorders with the modified release compositions is also described.